The Effect of Erythropoietin on Salpingitis during Ischemia Reperfusion Injury in Rats

Research Article

Austin J Reprod Med Infertil. 2015; 2(5): 1027.

The Effect of Erythropoietin on Salpingitis during Ischemia Reperfusion Injury in Rats

Tsompos C¹*, Panoulis C², Τοutouzas K³, Ζografos G4 and Papalois A5

¹Department of Obstetrics & Gynecology, Messolonghi County Hospital, Greece

²Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Greece

³Department of Surgery, Ippokrateion General Hospital, Athens University, Greece

4Department of Surgery, Ippokrateion General Hospital, Athens University, Greece

5Exprerimental Research Center ELPEN Pharmaceuticals, S.A. Inc., Co, Greece

*Corresponding author: Tsompos C, Department of Obstetrics & Gynecology, Mesologi County Hospital, Nafpaktou street, Mesologi 30200, Etoloakarnania, Greece

Received: June 09, 2015; Accepted: August 08, 2015; Published: August 10, 2015

Abstract

Purpose: This experimental study was to examine the effect of erythropoietin in a rat model and particularly in an oviducts Ischemia Reperfusion (IR) protocol. The effect of that molecule was studied pathologically using mean Salpingitis (S) lesions scores.

Methods: 40 rats of mean weight 247.7 g were used in the study. Salpingitis lesions were evaluated at 60 min (groups A and C) and at 120 min (groups B and D) of reperfusion. Erythropoietin was administered only in groups C and D.

Results: Epo administration non-significantly altered the salpingitis scores by 0 without lesions (p= 1.0000). Reperfusion time non-significantly altered the salpingitis scores by 0 without lesions (P= 1.0000). Furthermore, Epo administration and reperfusion time together non-significantly altered the salpingitis scores by 0 without lesions (p=1.0000).

Conclusion: Epo administration interacted or not with reperfusion time nonsignificantly short-term altered the salpingitis lesions scores. Perhaps, a longer study time than 2 hours may reveal more significant effects.

Keywords: Ischemia; Erythropoietin; Salpingitis; Reperfusion

Introduction

Tissue Ischemia and Reperfusion (IR) remain of the main causes of permanent or transient damage with serious implications on adjacent organs and certainly on patients’ health. Although important progress has been made regarding the usage of Erythropoietin (Epo) in managing this kind of damages, satisfactory answers have not been given yet to fundamental questions, as, by what velocity this factor acts, when it should be administered, and in which dosage. The particularly satisfactory action of Epo in stem blood cells recovery has been noted in several performed experiments. However, just few relative reports were found concerning Epo trial in IR experiments, not covering completely this particular matter. A meta-analysis of 13 published seric variables, coming from the same experimental setting, tried to provide a numeric evaluation of the Epo efficacy at the same endpoints (Table 1). Also, several publications addressed trials of other similar molecules of growth factors to which the studied molecule also belongs to.